Engineered for the biotherapeutic Race
Navigating the right path to achieve your goals— for your specific target
Choosing the right combination of immunogens, immunization schedules and species mitigates risk and ensures the best outcomes. Based on the characteristics of the antigen and starting material, we can develop peptides, proteins, or antibodies, suitable for customization from multiple immunization platforms.
At IPA, we know a full understanding of the target protein is critically important to a successful antibody campaign. Expert teams analyze each target and recommend the most effective way to deliver the product you need.
Antigen Modeling and Preparation
IPA has developed multiple strategies to select the correct domains of your target antigen (e.g., in silico modelling) and combine these antigens with the optimized immunization routes in different species. Depending on the characteristics of the individual antigen and the available starting material, we either generate synthetic peptides, recombinant proteins, antibodies, or antibody fragments (anti-idiotypic projects), cell lines suitable for immunization (syngeneic), or plasmids for genetic immunization (NonaVacTM). We can further immunize with smaller proteins or whole cell bacteria.
A multitude of immunization technologies are available at IPA, ranging from various injection methods to multiple genetic immunization applications to live whole cell-based immunizations.
Rapid Prime identifies positive monoclonal antibodies in as little as 32 days. This method is especially beneficial for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria.
After the immunization of rodents, we apply our proprietary electrofusion or PEG-fusion to generate hybridomas. The subsequent cloning, using semi-solid media and clone picking to accelerate the process, allows us to identify monoclonal antibody producing hybridoma cells, fast.
Rapid Prime immunization can also be combined with B cell Select or Phage Display.
Syngeneic Cell Line
Immunization of multiple species with a syngeneic cell line. After the selection of the species for the immunization, we discuss a suitable cell line and prepare transfected cells for immunization and screening.
Premium quality and purity
The success of your antibody development project is highly dependent on the quality of your antigen. IPA can produce your antigen at the scale and quality needed for immunization and use it seamlessly in a subsequent antibody discovery campaign.
In the case of anti-peptide projects, the immunizing antigen must be of high purity, enabled for carrier conjugation and safe for injection into animals. Therefore, to help ensure the best start to your antibody development projects, IPA’s scientists assist you in epitope prediction and antigen design. Our peptide production service also includes modifications such as phosphorylations.
Eligible French companies involved with us in research and development may receive a tax credit. Learn More.
1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118
Lead the way with IPA.
We have the longest memory
Rabbit monoclonal antibodies with B Cell Select® with Function-First from IPA are unmatched for early identification of a high affinity, highly specific antibodies.
Bispecifics & IPA
Bring us your scaffold and we can do the rest. With years of experience using a variety of bi- and multi-specific modalities, IPA has end-to-end capabilities and throughput to ensure selection and development of the most relevant therapeutic candidates.
Wet lab + in silico
LENSai in silico applications for radically informed decisions are designed to lend great cost and time efficiencies, as part of the IPA antibody discovery portfolio of service.
Additional antibody discovery products